Table S1.
The adjusted HRs with 95% CIs of drug discontinuation for adalimumab compared with etanercept on concomitant MTX >10 mg/wk during all treatment periods, ≤1 year or >1 year, stratified by other covariates with the significance of their modification effects
| Variable | All treatment periods (n =1,731)
|
Within 1 year (n=2,056)
|
After 1 year (n=606)
|
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | P for modification | HR (95% CI) | P for modification | HR (95% CI) | P for modification | |
| Age | 0.312 | 0.163 | 0.209 | |||
| <65 years | 1.23 (1.04–1.45) | 1.39 (1.12–1.71) | 1.19 (0.86–1.66) | |||
| ≥65 years | 1.50 (1.10–2.05) | 1.89 (1.24–2.89) | 4.14 (1.94–8.80) | |||
| Sex | 0.911 | 0.440 | 0.240 | |||
| Female | 1.27 (1.08–1.50) | 1.52 (1.23–1.89) | 1.28 (0.92–1.77) | |||
| Male | 1.36 (0.995–1.87) | 1.37 (0.89–2.08) | 1.80 (0.89–3.63) | |||
| Disease duration | 0.255 | 0.338 | 0.913 | |||
| <3 years | 1.12 (0.85–1.48) | 1.26 (0.88–1.79) | 1.41 (0.75–2.65) | |||
| ≥3 years | 1.38 (1.17–1.63) | 1.61 (1.28–2.02) | 1.42 (1.01–1.99) | |||
| History within 1 year before anti-TNF treatment | ||||||
| CCI | 0.114 | 0.681 | <0.001 | |||
| <2 | 1.18 (0.98–1.43) | 1.46 (1.13–1.88) | 0.90 (0.60–1.35) | |||
| ≥2 | 1.44 (1.16–1.79) | 1.58 (1.19–2.11) | 2.51 (1.58–3.99) | |||
| MTX, mg/wk | 0.013 | 0.912 | <0.001 | |||
| ≤10 | 0.94 (0.71–1.24) | 1.47 (1.02–2.11) | 0.50 (0.27–0.92) | |||
| >10 | 1.43 (1.21–1.69) | 1.51 (1.21–1.88) | 2.06 (1.47–2.90) | |||
| SSZ | 0.172 | 0.489 | 0.796 | |||
| No | 1.49 (1.09–2.03) | 1.28 (0.86–1.91) | 1.92 (0.95–3.87) | |||
| Yes | 1.23 (1.04–1.44) | 1.56 (1.25–1.93) | 1.41 (1.02–1.95) | |||
| LEF | 0.755 | 0.552 | 0.490 | |||
| No | 1.26 (1.07–1.50) | 1.53 (1.23–1.91) | 1.36 (0.94–1.98) | |||
| Yes | 1.34 (1.03–1.76) | 1.38 (0.95–2.00) | 1.62 (0.99–2.65) | |||
| HCQ | 0.046 | 0.310 | 0.093 | |||
| No | 1.88 (1.30–2.71) | 1.99 (1.19–3.34) | 2.74 (1.33–5.66) | |||
| Yes | 1.20 (1.02–1.40) | 1.42 (1.16–1.75) | 1.22 (0.88–1.69) | |||
| NSAID | 0.212 | 0.275 | 0.864 | |||
| No | a | a | a | |||
| Yes | 1.28 (1.11–1.48) | 1.49 (1.23–1.80) | 1.41 (1.05–1.89) | |||
| Pd equivalent | 0.111 | 0.426 | 0.040 | |||
| ≤5 mg/d | 1.12 (0.88–1.42) | 1.43 (1.06–1.94) | 0.80 (0.46–1.37) | |||
| >5 mg/d | 1.38 (1.45–1.65) | 1.50 (1.17–1.91) | 1.89 (1.32–2.71) | |||
| Comedication | ||||||
| SSZ | 0.261 | 0.391 | 0.472 | |||
| No | 1.42 (1.14–1.75) | 1.39 (1.05–1.83) | 1.28 (0.87–1.86) | |||
| Yes | 1.19 (0.98–1.45) | 1.61 (1.24–2.09) | 1.58 (0.99–2.53) | |||
| LEF | 0.449 | 0.492 | 0.409 | |||
| No | 1.26 (1.08–1.47) | 1.45 (1.19–1.78) | 1.49 (1.09–2.03) | |||
| Yes | 1.51 (1.02–2.21) | 1.86 (1.07–3.23) | 1.02 (0.41–2.55) | |||
| HCQ | 0.990 | 0.633 | 0.385 | |||
| No | 1.35 (1.05–1.72) | 1.41 (1.01–1.96) | 1.51 (0.99–2.29) | |||
| Yes | 1.25 (1.05–1.50) | 1.51 (1.20–1.91) | 1.25 (0.82–1.91) | |||
| NSAID | 0.101 | 0.361 | 0.683 | |||
| No | 1.17 (0.29–4.65) | 1.34 (0.42–4.24) | 7.89 (0.09–724.89) | |||
| Yes | 1.29 (1.12–1.49) | 1.51 (1.25–1.83) | 1.44 (1.06–1.94) | |||
| Pd equivalent | 0.186 | 0.806 | 0.585 | |||
| ≤5 mg/d | 1.18 (0.98–1.43) | 1.42 (1.10–1.82) | 1.41 (1.00–1.99) | |||
| >5 mg/d | 1.43 (1.15–1.78) | 1.57 (1.17–2.10) | 1.62 (0.88–3.01) | |||
Notes: Cox proportional hazard regression analyses were conducted to calculate adjusted HRs after adjusting for sex, age at anti-TNF initiation (≤65 years, >65 years), disease duration (≤3 years, >3 years), CCI (≤1, >2) within 1 year before anti-TNF use, use of LEF, SSZ, NSAID, MTX (0–10 mg/wk, >10 mg/wk), and corticosteroid (Pd equivalent ≤5 mg/d, >5 mg/d) within 1 year before and after anti-TNF use.
95% CI was very large and covered one (ie, nonsignificant).
Abbreviations: HRs, hazard ratios; CI, confidence intervals; MTX, methotrexate; TNF, tumor necrosis factor; CCl, Charlson comorbidity index; SSZ, salazopyrin; LEF, leflunomide; HCQ, hydroxychloroquine; NSAID, nonsteroid anti-inflammatory drug; Pd, prednisolone.